Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN:US74154B2034)
TO PRESENT AT ASX SMALL TO MID CAPS CONFERENCE IN HONG KONG
Prima BioMed Ltd (ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034)
announces that its CEO Matthew Lehman will present a corporate update at the ASX Small to Mid Caps conference to be held in Hong Kong on October 18, 2012.
Approximately one week after the event, a video webcast of the presentation will be available from the conference organizer. A copy of the presentation to be delivered is appended to this announcement.
Prima BioMed is a globally active biotechnology company headquartered in Australia. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology
and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima s lead product is CVac , an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.
For further information please
Australia Investor/Media:
Mr. James Moses, Mandate Corporate
+61 (0) 420 991 574; james@mandatecorporate.com.au
Ms. Kathy Galante, Burns
+1 (212) 213-0006; kgalante@burnsmc.com
Europe Investor/Media:
Mr. Axel M hlhaus, edicto GmbH
+49 (0) 69 905505-52; amuehlhaus@edicto.de
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
2 9276 1224 Fax: +61 2 9276 1284